WHIPPANY, New Jersey, May 7 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news on May 6, 2026:

* * *

Bayer announces new late-breaking data from OCEANIC-STROKE trial of asundexian

Data evaluates the frequency, severity, and disability of ischemic strokes in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack

KEY FINDINGS